SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) October 1, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. (Nasdaq:BICO) announced
today that it has entered into Distribution and
Licensing Agreements with Luther Medical Products,
Inc., in Tustin, Calif., for its theraPORTr vascular
access system product line. The theraPORT is a totally
implantable device intended for use with patients that
require repeated venous access for injection for infusion
therapy and venous blood sampling. It is primarily used
for the infusion of chemotherapeutic drugs. The newest
addition to the theraPORT product line, the theraPORT
low-profile vascular access system, was approved by
the FDA for sale in the U.S. earlier this year and is
appropriate for use in pediatric patients. Luther purchased
a nonexclusive license to Biocontrol's technology for the
theraPORT and plans to eventually manufacture the devices at
its Tustin, Calif. location.
Item 6. Resignation of Registrant's Directors.
Not Applicable.
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: October 1, 1998
BIOCONTROL TECHNOLOGY, INC.
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL AND LUTHER MEDICAL PRODUCTS SIGN AGREEMENTS
Pittsburgh, PA - October 1, 1998 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that the company has entered into
Distribution and Licensing Agreements with Luther Medical
Products, Inc., in Tustin, Calif., for its theraPORTr vascular
access system product line.
The theraPORT is a totally implantable device intended for
use with patients that require repeated venous access for
injection for infusion therapy and venous blood sampling. It is
primarily used for the infusion of chemotherapeutic drugs. The
newest addition to the theraPORT product line, the theraPORT low-
profile vascular access system, was approved by the FDA for sale
in the U.S. earlier this year and is appropriate for use in
pediatric patients.
Luther purchased a nonexclusive license to Biocontrol's
technology for the theraPORT and plans to eventually manufacture
the devices at its Tustin, Calif. location. Until manufacture is
established and all regulatory approvals received, Luther will
distribute the Biocontrol product in the U.S. under the
Biocontrol label for approximately one year. Biocontrol will
continue to sell its Indiana, Pa. - manufactured product in the
U.S., and plans to expand sales into the European Union as soon
as possible. Details of the distribution agreement have not been
disclosed due to the confidential nature of both companies'
pricing information.
Luther has been in business in California since 1980 and has
been primarily engaged in the design, development, manufacture,
sale, and licensing of intra-vascular catheters and split, peel-
away needles for the delivery of plasma, blood, chemotherapy,
intravenous drugs, and feeding solutions. It has agreements with
17 distributors located across the U.S. with approximately 120
salespersons active in selling its products.
Biocontrol Technology, Inc. (www.bico.com) has its corporate
offices in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
This press release contains forward looking statements and
shareholders and potential investors are cautioned that
such statements are predictions and actual events or results may
vary significantly.
